Mineralys Narrows Losses, Boosts Cash with $459M in Offerings

TL;DR

**MLYS is burning cash but just raised a ton, giving them a longer runway to get lorundrostat to market; watch for trial results.**

AI Summary

Mineralys Therapeutics, Inc. (MLYS) reported a net loss of $36.9 million for the three months ended September 30, 2025, a significant improvement from the $56.3 million net loss in the same period of 2024. For the nine months ended September 30, 2025, the net loss was $122.4 million, down from $128.9 million in 2024. Research and development expenses decreased to $31.5 million for the quarter from $54.0 million in 2024, and to $107.6 million for the nine months from $124.0 million in 2024, reflecting the completion of two pivotal clinical trials for lorundrostat. General and administrative expenses increased to $9.7 million for the quarter from $6.1 million in 2024, and to $24.7 million for the nine months from $16.6 million in 2024. The company's cash, cash equivalents, and investments surged to $593.6 million as of September 30, 2025, up from $191.3 million at December 31, 2024, primarily due to successful public offerings that raised approximately $459.1 million net. MLYS continues to fund operations through equity offerings, having raised approximately $1.0 billion in gross proceeds since inception, and expects its current capital to fund operations for at least 12 months.

Why It Matters

This filing is crucial for investors as Mineralys Therapeutics, a clinical-stage biopharmaceutical company, has significantly bolstered its cash reserves to $593.6 million through recent public offerings, providing a longer runway for its drug development. The reduction in net loss and R&D expenses, while still substantial, indicates progress in managing costs as key clinical trials for lorundrostat conclude. For employees, this financial stability suggests continued investment in their programs. Customers and the broader market will be watching for the potential impact of lorundrostat, especially given the competitive landscape in hypertension and cardiorenal conditions, where effective new treatments could be highly disruptive.

Risk Assessment

Risk Level: medium — The company has an accumulated deficit of $424.9 million as of September 30, 2025, and has not generated any revenue from product sales, indicating a high operational risk. However, the cash, cash equivalents, and investments of $593.6 million provide sufficient liquidity for at least 12 months, mitigating immediate going concern risks.

Analyst Insight

Investors should monitor upcoming clinical trial results for lorundrostat, particularly for the ongoing Phase 2 trial in obstructive sleep apnea, as these will be critical catalysts. Given the significant cash position, MLYS has the capital to advance its pipeline, but continued losses mean future dilution or debt financing remains a possibility.

Financial Highlights

debt To Equity

0.00

revenue

N/A

operating Margin

N/A

total Assets

$ 599.9M

total Debt

$ 0.00

net Income

$ -122.4M

eps

$ -1.94

gross Margin

N/A

cash Position

$ 593.6M

revenue Growth

N/A

Key Numbers

• $593.6M — Cash, cash equivalents, and investments (Increased from $191.3 million at December 31, 2024, providing a longer liquidity runway.)
• $122.4M — Net loss for nine months ended September 30, 2025 (Improved from $128.9 million in the prior year, indicating a slight reduction in losses.)
• $107.6M — Research and development expenses for nine months ended September 30, 2025 (Decreased from $124.0 million in the prior year, reflecting completion of pivotal trials.)
• $494.3M — Net cash provided by financing activities for nine months ended September 30, 2025 (Significantly increased from $116.1 million in the prior year, primarily from public offerings.)
• $424.9M — Accumulated deficit as of September 30, 2025 (Indicates continued operational losses since inception.)
• 79,139,956 — Shares of common stock outstanding as of November 3, 2025 (Increased due to recent equity offerings, indicating dilution for existing shareholders.)
• $1.0B — Aggregate gross proceeds raised since inception (Highlights the company's reliance on capital markets for funding.)

Key Players & Entities

• Mineralys Therapeutics, Inc. (company) — registrant
• lorundrostat (product) — clinical-stage product candidate
• U.S. Securities and Exchange Commission (regulator) — governing body for financial reporting
• Nasdaq Stock Market LLC (company) — exchange where MLYS common stock is registered
• Delaware (location) — state of incorporation
• Radnor, Pennsylvania (location) — company headquarters
• Chief Executive Officer (person) — chief operating decision maker (CODM)

FAQ

Risk Factors

• Reliance on Equity Financing [high — financial]: Mineralys Therapeutics relies heavily on equity offerings for funding, having raised approximately $1.0 billion in gross proceeds since inception. The company expects its current capital of $593.6 million as of September 30, 2025, to fund operations for at least 12 months, indicating a continued need for external capital to sustain operations and development.
• Clinical Trial Completion and Future Development [medium — operational]: The decrease in R&D expenses to $107.6 million for the nine months ended September 30, 2025, from $124.0 million in the prior year, is attributed to the completion of two pivotal clinical trials for lorundrostat. Future R&D spending will depend on the outcomes of these trials and the progression of other pipeline candidates.
• Increasing General and Administrative Expenses [medium — operational]: General and administrative expenses have increased to $24.7 million for the nine months ended September 30, 2025, from $16.6 million in the same period of 2024. This rise, from $9.7 million in Q3 2025 compared to $6.1 million in Q3 2024, may indicate increased operational overhead as the company prepares for potential commercialization or further development stages.
• Accumulated Deficit [high — financial]: The company has an accumulated deficit of $424.9 million as of September 30, 2025. This reflects the cumulative losses incurred since its inception, underscoring the high-risk nature of biotechnology investments and the need for significant future revenue generation or financing.
• Dilution from Equity Offerings [medium — financial]: The number of outstanding shares of common stock increased to 79,139,956 as of November 3, 2025, due to recent equity offerings. This increase, from 49,821,915 shares outstanding at December 31, 2024, indicates significant dilution for existing shareholders.

Industry Context

The biotechnology sector is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Companies like Mineralys Therapeutics often rely on substantial external financing to fund their operations until a product generates revenue. The competitive landscape is driven by innovation, patent protection, and the ability to navigate clinical trials and regulatory approvals successfully.

Regulatory Implications

Mineralys Therapeutics is subject to stringent regulatory oversight by bodies such as the FDA. The successful completion of clinical trials for lorundrostat is a critical step towards potential drug approval. Any delays or adverse findings in ongoing or future regulatory reviews could significantly impact the company's development timeline and commercial prospects.

What Investors Should Do

1. Monitor R&D Pipeline Progression
2. Assess Burn Rate and Future Financing Needs
3. Evaluate G&A Expense Growth

Key Dates

• 2025-09-30: Quarterly Financial Reporting — Reported a net loss of $36.9 million for Q3 2025 and $122.4 million for the nine months ended, with a strong cash position of $593.6 million.
• 2025-12-31: Previous Year-End Reporting — Reported a cash position of $191.3 million and a net loss of $128.9 million for the nine months ended September 30, 2024.
• 2025-11-03: Shares Outstanding Update — Common stock outstanding reached 79,139,956, reflecting dilution from recent equity raises.

Glossary

Accumulated deficit

The total net losses of a company since its inception, minus any net profits. It represents the cumulative loss that has not been offset by profits. (Indicates the company has not yet achieved profitability and has relied on external funding to cover its expenses.)

Lorundrostat

A drug candidate developed by Mineralys Therapeutics, Inc. for which pivotal clinical trials have been completed. (The completion of its trials is a key factor influencing R&D expenses and future development strategy.)

Pre-funded warrants

A type of warrant that allows the holder to purchase shares of stock at a specified price, but with a pre-funded component that effectively means the shares are already partially paid for. (These were part of a private placement offering, contributing to the increase in capital and shares issued.)

Stock-based compensation

Compensation provided to employees in the form of stock or stock options, rather than cash. (This is a non-cash expense that impacts net loss and equity, as seen in the increase in additional paid-in capital and common stock.)

Year-Over-Year Comparison

Mineralys Therapeutics has significantly improved its cash position, increasing from $191.3 million at December 31, 2024, to $593.6 million as of September 30, 2025, primarily due to successful equity offerings. While the net loss for the nine-month period slightly decreased from $128.9 million to $122.4 million, and R&D expenses fell from $124.0 million to $107.6 million due to trial completions, general and administrative expenses rose from $16.6 million to $24.7 million. The number of outstanding shares has also increased substantially, indicating dilution.

Key Financial Figures

• $0.0001 — nge on which registered Common stock, $0.0001 par value per share MLYS The Nasdaq S

Filing Documents

• mlys-20250930.htm (10-Q) — 758KB
• mlys2025q310qex311.htm (EX-31.1) — 9KB
• mlys2025q310qex312.htm (EX-31.2) — 9KB
• mlys2025q310qex321.htm (EX-32.1) — 5KB
• mlys2025q310qex322.htm (EX-32.2) — 5KB
• 0001933414-25-000142.txt ( ) — 3764KB
• mlys-20250930.xsd (EX-101.SCH) — 27KB
• mlys-20250930_cal.xml (EX-101.CAL) — 32KB
• mlys-20250930_def.xml (EX-101.DEF) — 121KB
• mlys-20250930_lab.xml (EX-101.LAB) — 379KB
• mlys-20250930_pre.xml (EX-101.PRE) — 256KB
• mlys-20250930_htm.xml (XML) — 360KB

- Financial Information

Part I - Financial Information 1

Financial Statements

Item 1. Financial Statements 1

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 17

Quantitative and Qualitative Disclosures About Market Risk

Item 3. Quantitative and Qualitative Disclosures About Market Risk 32

Controls and Procedures

Item 4. Controls and Procedures 33

- Other Information

Part II - Other Information 34

Legal Proceedings

Item 1. Legal Proceedings 34

Risk Factors

Item 1A. Risk Factors 34

Unregistered Sales of Equity Securities and Use of Proceeds

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 36

Defaults Upon Senior Securities

Item 3. Defaults Upon Senior Securities 36

Mine Safety Disclosures

Item 4. Mine Safety Disclosures 36

Other Information

Item 5. Other Information 36

Exhibits

Item 6. Exhibits 36 i Table of Contents

- Financial Information

Part I - Financial Information

Financial Statements

Item 1. Financial Statements Mineralys Therapeutics, Inc. Condensed Balance Sheets (in thousands, except share and per share amounts) September 30, December 31, 2025 2024 (unaudited) Assets Current assets: Cash and cash equivalents $ 217,597 $ 114,091 Investments 376,031 84,096 Prepaid and other current assets 6,168 7,164 Total current assets 599,796 205,351 Property and equipment, net 7 53 Other assets 144 499 Total assets $ 599,947 $ 205,903 Liabilities and stockholders' equity Current liabilities: Accounts payable $ 1,121 $ 479 Accrued liabilities 22,399 14,167 Total current liabilities 23,520 14,646 Commitments and contingencies (Note 4) Stockholders' equity: Common stock, $ 0.0001 par value; 500,000,000 shares authorized as of September 30, 2025 and December 31, 2024; 78,969,459 and 49,821,915 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively 8 5 Additional paid-in capital 1,001,354 493,770 Accumulated deficit ( 424,935 ) ( 302,518 ) Total stockholders' equity 576,427 191,257 Total liabilities and stockholders' equity $ 599,947 $ 205,903 The accompanying notes are an integral part of these condensed financial statements. 1 Table of Contents Mineralys Therapeutics, Inc. Condensed Statements of Operations (in thousands, except share and per share data) (unaudited) Three Months Ended Nine Months Ended September 30, September 30, 2025 2024 2025 2024 Operating expenses: Research and development $ 31,450 $ 53,985 $ 107,607 $ 124,012 General and administrative 9,681 6,121 24,717 16,624 Total operating expenses 41,131 60,106 132,324 140,636 Loss from operations ( 41,131 ) ( 60,106 ) ( 132,324 ) ( 140,636 ) Interest income, net 4,195 3,774 9,908 11,779 Other income (expense) 4 ( 10 ) ( 1 ) ( 7 ) Total other income, net 4,199 3,764 9,907 11,772 Net loss $ ( 36,932 ) $ ( 56,342 ) $ ( 122,417 ) $ ( 128,864 ) Net loss per share attributable to common stockholders, basic and

View Full Filing

View this 10-Q filing on SEC EDGAR